ClinicalTrials.Veeva

Menu

Efficacy of Laser Hair Removal Therapy in HS (HaLa)

Erasmus University logo

Erasmus University

Status

Not yet enrolling

Conditions

Hidradenitis Suppurativa, Acne Inversa

Treatments

Drug: Clindamycin 1 % Topical Lotion
Procedure: Nd:YAG laser hair removal

Study type

Interventional

Funder types

Other

Identifiers

NCT05762484
EMCD_22026

Details and patient eligibility

About

Hidradenitis suppurativa (HS) is a chronic, recurrent and debilitating inflammatory skin disorder, characterized by painful inflamed nodules, abscesses and tunnels in the skin folds such as the axilla, inguinal region and gluteal area. The primary event in HS is occlusion of the hair follicle. HS is a notoriously difficult to treat disease, because treatment options are limited and evidence based treatments are scarce. Prevention of diseases is an important topic in medicine. However, current clinical trials in HS are focusing on anti-inflammatory drugs in patients with severe HS, whereas prevention and treatment of patients with more common mild HS is neglected. Laser hair removal therapy is a non-invasive procedure with minimal treatment discomfort for patients. Previous limited studies have suggested positive results in favor of laser hair removal therapy in HS. We therefore hypothesize that hair depilation using laser hair removal therapy may prevent the formation of new lesions and flares of the disease. The objective is to assess the efficacy of laser hair removal therapy in patients with mild to moderate HS.

Enrollment

58 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • IHS4 mild to moderate, without tunnels in the axillae.
  • HS activity in at least one axilla.
  • Age 18 years and over.

Exclusion criteria

  • If the patient is not able or willing to provide informed consent.
  • If the patient is allergic to clindamycin lotion.
  • If the patient uses systemic therapy for HS such as antibiotics or biologicals.
  • If a patient is pregnant.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

58 participants in 2 patient groups

Intervention group, laser hair removal therapy
Experimental group
Description:
Patients will undergo 6 monthly laser hair removal treatments with de Nd:YAG laser. After 6 months, a 6 follow up will start, using clindamycin 1% lotion if needed.
Treatment:
Procedure: Nd:YAG laser hair removal
Control group, clindamycin 1% lotion if needed, standard care
Active Comparator group
Description:
Patients will use clindamycin 1% lotion of needed for 1 year.
Treatment:
Drug: Clindamycin 1 % Topical Lotion

Trial contacts and locations

0

Loading...

Central trial contact

Hessel van der Zee, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems